Last reviewed · How we verify
NCT05033054
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
trial testing SGLT2 inhibitor in Kidney Disease, Chronic in 33 participants. Completed in 1 February 2025.
2 January 2025
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 1 January 2022 |
| Primary completion | 2 January 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SGLT2 inhibitor — full drug profile →
Conditions studied
- Kidney Disease, Chronic — all drugs for Kidney Disease, Chronic →
- Diabetes — all drugs for Diabetes →
Sponsor
University of Texas Southwestern Medical Center
Who can join
Adults 18 to 80, any sex, with Kidney Disease, Chronic or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, observational study to assess the effect of SGLT2 inhibitors on surrogate markers of kidney and cardiovascular health in patients with stage 3b and 4 chronic kidney disease (CKD). This study includes three clinic in person visits and weekly telephone visits for 12 weeks. 1. Recruit 28 patients with CKD stages 3b-4 and follow up for 12 weeks 2. Determine the effect of interventions on the primary outcome variable serum klotho measured by immunoprecipitation-immunoblot
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Klotho's impact on diabetic nephropathy and its emerging connection to diabetic retinopathy.
Tang A, Zhang Y, Wu L, Lin Y, et al · · 2023 · cited 35× · PMID 37143722 · DOI 10.3389/fendo.2023.1180169 -
Magnesium Administration in Chronic Kidney Disease.
Vermeulen EA, Vervloet MG. · · 2023 · cited 20× · PMID 36771254 · DOI 10.3390/nu15030547 -
The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus.
Sumaily KM. · · 2022 · cited 9× · PMID 35807813 · DOI 10.3390/nu14132632 -
Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.
González-Albarrán O, Morales C, Pérez-Maraver M, Aparicio-Sánchez JJ, et al · · 2022 · cited 8× · PMID 35704167 · DOI 10.1007/s13300-022-01276-2
Verify or expand the search:
- PubMed search for NCT05033054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT2 inhibitor
Trials testing the same drug.
- NCT07360457 — GLP1 Analogues and the Risk of Osteoarthritis · not yet recruiting
- NCT07172971 — Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Phase 1 · not yet recruiting
- NCT07334145 — Effect of SGLT2 Inhibitors on Anemic CKD Patients · not yet recruiting
- NCT07063316 — SGLT2 Inhibitors and Renal Anemia in Japan: RWD · active not recruiting
- NCT06350487 — The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction · Phase 4 · not yet recruiting
Other recruiting trials for Kidney Disease, Chronic
Currently open trials in the same condition.
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
- NCT06701825 — Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus · Phase 4 · recruiting
- NCT06830473 — KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection · recruiting
- NCT06863194 — Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial · Phase 1, PHASE2 · recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05033054 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 12 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05033054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing